Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Lua WilkinsonThomas Holst-HansenPeter N LaursenAnders R RinnovRachel L Batterham W Timothy Garvey

Published in: Obesity (Silver Spring, Md.) (2023)

Cardiometabolic Disease Staging risk assessment suggests that once-weekly semaglutide 2.4 mg may substantially lower 10-year T2D risk in people with overweight or obesity.

Keyphrases

type diabetes
weight loss
weight gain
insulin resistance
risk assessment
metabolic syndrome
high fat diet induced
body mass index
cardiovascular disease
lymph node
adipose tissue
human health
heavy metals
pet ct